Sol-Gel Technologies Ltd. (NASDAQ:SLGL) Stock Now Rated "Moderate Buy" by Sell-Side Analysts

Key Points

• Analyst consensus is “Moderate Buy” for Sol-Gel Technologies, with three buys, one strong buy, one hold and one sell among six analysts. The average 12-month price target is $197.50, versus a recent share price of $74.28.
• The company reported a quarterly loss of $1.13 per share, beating estimates for a $2.36 loss, while revenue of $0.59 million exceeded the $0.07 million consensus forecast. Analysts expect a full-year loss of approximately $4.95 per share.
• Insider and institutional interest remains notable: Opaleye Management purchased 35,113 shares, and insiders bought nearly $3.7 million of stock over the past 90 days. Insiders own 66.51% of the company, while institutional investors and hedge funds own 26.18%.

Shares of Sol-Gel Technologies Ltd. (NASDAQ:SLGL - Get Free Report) have been assigned a consensus rating of "Moderate Buy" from the six research firms that are covering the firm, Marketbeat Ratings reports. One research analyst has rated the stock with a sell rating, one has issued a hold rating, three have assigned a buy rating and one has assigned a strong buy rating to the company. The average 1-year target price among analysts that have issued ratings on the stock in the last year is $197.50.

Several brokerages recently commented on SLGL. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Sol-Gel Technologies in a research report on Tuesday, September 1st. Mizuho began coverage on Sol-Gel Technologies in a report on Wednesday, June 24th. They set an "outperform" rating and a $285.00 price objective for the company. Finally, HC Wainwright reaffirmed a "buy" rating and issued a $110.00 target price on shares of Sol-Gel Technologies in a research report on Monday, July 20th.

Sol-Gel Technologies Trading Up 2.8%

Shares of SLGL opened at $74.28 on Thursday. Sol-Gel Technologies has a 12-month low of $27.00 and a 12-month high of $97.97. The stock has a market cap of $208.73 million, a P/E ratio of -13.17 and a beta of 1.12. The company has a 50-day moving average of $74.31 and a two-hundred day moving average of $74.54.

Sol-Gel Technologies (NASDAQ:SLGL - Get Free Report) last released its quarterly earnings results on Friday, August 21st. The company reported ($1.13) EPS for the quarter, beating the consensus estimate of ($2.36) by $1.23. The business had revenue of $0.59 million for the quarter, compared to analyst estimates of $0.07 million. Sol-Gel Technologies had a negative net margin of 910.14% and a negative return on equity of 44.05%. As a group, analysts forecast that Sol-Gel Technologies will post -4.95 EPS for the current fiscal year.

Insider Activity at Sol-Gel Technologies

In related news, major shareholder Opaleye Management Inc. purchased 35,113 shares of Sol-Gel Technologies stock in a transaction that occurred on Friday, August 28th. The shares were purchased at an average cost of $69.32 per share, with a total value of $2,434,033.16. Following the transaction, the insider owned 520,000 shares of the company's stock, valued at approximately $36,046,400. The trade was a 7.24% increase in their position. The purchase was disclosed in a filing with the SEC, which can be accessed through this link. Insiders bought a total of 53,959 shares of company stock worth $3,723,781 in the last 90 days. Insiders own 66.51% of the company's stock.

Institutional Inflows and Outflows

An institutional investor recently bought a new stake in Sol-Gel Technologies stock. Affinity Asset Advisors LLC purchased a new position in shares of Sol-Gel Technologies Ltd. (NASDAQ:SLGL - Free Report) during the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm purchased 35,000 shares of the company's stock, valued at approximately $2,773,000. Affinity Asset Advisors LLC owned about 1.25% of Sol-Gel Technologies as of its most recent filing with the Securities and Exchange Commission (SEC). 26.18% of the stock is owned by institutional investors and hedge funds.

About Sol-Gel Technologies

Sol-Gel Technologies Ltd. is an Israeli specialty pharmaceutical company focused on developing topical dermatological treatments. The company uses proprietary microencapsulation technology designed to improve the delivery, stability, and tolerability of active pharmaceutical ingredients applied to the skin.

Sol-Gel's products include TWYNEO Cream, a topical combination of tretinoin and benzoyl peroxide for acne, and EPSOLAY Cream, a microencapsulated benzoyl peroxide treatment for inflammatory lesions associated with rosacea.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.